{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+%28Oral%29", "query": { "intervention": "Dexamethasone (Oral)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 741, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+%28Oral%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T06:21:53.847Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00022737", "title": "Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Lymphoblastic Leukemia in Remission", "Recurrent Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine tablet", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 220, "start_date": "2002-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-27", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022737" }, { "nct_id": "NCT04503668", "title": "Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gynecologic Cancer" ], "interventions": [ { "name": "Ondansetron", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Neurokinin-1 Receptor Antagonist (NK1-RA)", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Compazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "FEMALE", "summary": "18 Years to 89 Years · Female only" }, "enrollment_count": 62, "start_date": "2020-12-28", "completion_date": "2024-03-11", "has_results": true, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04503668" }, { "nct_id": "NCT04882163", "title": "Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-10", "completion_date": "2029-04-07", "has_results": false, "last_update_posted_date": "2021-10-05", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04882163" }, { "nct_id": "NCT02179892", "title": "Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Bupivacaine Extended-Release Liposome Injection (Exparel)", "type": "DRUG" }, { "name": "Bupivacaine and Dexamethasone Injection", "type": "DRUG" }, { "name": "IV Acetaminophen", "type": "DRUG" }, { "name": "Oral Acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colette Curtis MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-07", "completion_date": "2015-06-06", "has_results": true, "last_update_posted_date": "2017-08-11", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02179892" }, { "nct_id": "NCT00905034", "title": "Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Acute" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "PEG-l-asparaginase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 37, "start_date": "2009-03", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2015-06-29", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00905034" }, { "nct_id": "NCT06824467", "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "H1 receptor antagonist", "type": "DRUG" }, { "name": "H2 receptor antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid mouthwash (dexamethasone or equivalent)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 770, "start_date": "2025-04-09", "completion_date": "2032-11-09", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "San Francisco", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06824467" }, { "nct_id": "NCT06383572", "title": "Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphodepleting Chemotherapy", "Myeloid Malignancies" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 44, "start_date": "2024-06-26", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06383572" }, { "nct_id": "NCT02047253", "title": "Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2014-04", "completion_date": "2017-07-14", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Macon, Georgia • New Orleans, Louisiana", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Macon", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047253" }, { "nct_id": "NCT03313557", "title": "AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Wee-1 kinase inhibitor AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 48, "start_date": "2017-10-27", "completion_date": "2019-05-17", "has_results": false, "last_update_posted_date": "2019-06-24", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 7, "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more", "locations": [ { "city": "Bingham Farms", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03313557" }, { "nct_id": "NCT03168100", "title": "2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2017-10-01", "completion_date": "2019-01-24", "has_results": false, "last_update_posted_date": "2019-01-28", "last_synced_at": "2026-09-23T06:21:53.847Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03168100" } ] }